Corticotroph tumor progression speed after adrenalectomy

被引:2
|
作者
Bessiene, Laura [1 ]
Moutel, Sandrine [1 ]
Lataud, Marine [4 ]
Jouinot, Anne [1 ,7 ]
Bonnet-Serrano, Fideline [2 ,7 ]
Guibourdenche, Jean [2 ]
Villa, Chiara [3 ,7 ]
Baussart, Bertrand [5 ,7 ]
Gaillard, Stephan [5 ,7 ]
Barat, Maxime [4 ,7 ]
Dohan, Anthony [4 ,7 ]
Bertagna, Xavier [1 ,7 ]
Dousset, Bertrand [6 ,7 ]
Bertherat, Jerome [1 ,7 ]
Assie, Guillaume [1 ,7 ]
机构
[1] Hop Cochin, AP HP, Reference & Competence Ctr Rare Adrenal Dis & Rar, Dept Endocrinol, Paris, France
[2] Hop Cochin, AP HP, Dept Hormonol, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Dept Pathol Cytol & Anat, Paris, France
[4] Hop Cochin, AP HP, Dept Radiol, Paris, France
[5] Hop La Pitie Salpetriere, AP HP, Dept Neurosurg, Paris, France
[6] Hop Cochin, AP HP, Dept Visceral & Endocrine Surg, Paris, France
[7] Univ Paris Cite, Inst Cochin, CNRS, INSERM,U1016,UMR8104, F-75014 Paris, France
关键词
CUSHINGS-DISEASE; BILATERAL ADRENALECTOMY; NELSONS-SYNDROME; STEREOTACTIC RADIOSURGERY; ADRENOCORTICOTROPIN; RECURRENCE; MORTALITY; SURGERY; RISK;
D O I
10.1530/EJE-22-0536
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesAfter bilateral adrenalectomy in Cushing's disease, corticotroph tumor progression occurs in one-third to half of patients. However, progression speed is variable, ranging from slow to rapid. The aim was to explore corticotroph progression speed, its consequences and its risk factors. DesignA retrospective single-center observational study. MethodsIn total,103 patients with Cushing's disease who underwent bilateral adrenalectomy between 1990 and 2020 were included. Clinical, biological, histological and MRI features were collected. Median duration of follow-up after bilateral adrenalectomy was 9.31 years. ResultsIn total,44 patients progressed (43%). Corticotroph tumor progression speed ranged from 1 to 40.7 mm per year. Progression speed was not different before and after bilateral adrenalectomy (P = 0.29). In univariate analyses, predictive factors for rapid corticotroph tumor progression included the severity of Cushing's disease before adrenalectomy as the cause of adrenalectomy, high ACTH in the year following adrenalectomy and high Ki67 immunopositivity in the tumor. During follow-up, early morning ACTH absolute variation was associated with corticotroph tumor progression speed (P-value = 0.001). ACTH measurement after dynamic testing did not improve this association. ConclusionAfter adrenalectomy, corticotroph progression speed is highly variable and manageable with MRI and ACTH surveillance. Progression speed does not seem related to bilateral adrenalectomy but rather to intrinsic properties of highly proliferative and secreting tumors.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 50 条
  • [1] Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN
    Valassi, Elena
    Castinetti, Frederic
    Ferriere, Amandine
    Tsagarakis, Stylianos
    Feelders, Richard A.
    Netea-Maier, Romana T.
    Droste, Michael
    Strasburger, Christian J.
    Maiter, Dominique
    Kastelan, Darko
    Chanson, Philippe
    Webb, Susan M.
    Demtroder, Frank
    Pirags, Valdis
    Chabre, Olivier
    Franz, Holger
    Santos, Alicia
    Reincke, Martin
    [J]. ENDOCRINE-RELATED CANCER, 2022, 29 (12) : 681 - 691
  • [2] Corticotroph tumor progression after adrenalectomy in Cushing's disease:: A reappraisal of Nelson's syndrome
    Assie, Guillaume
    Bahurel, Helene
    Coste, Joel
    Silvera, Stephane
    Kujas, Michele
    Dugue, Marie-Annick
    Karray, Foued
    Dousset, Bertrand
    Bertherat, Jerome
    Legmann, Paul
    Bertagna, Xavier
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01): : 172 - 179
  • [3] Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations
    Reincke, Martin
    Albani, Adriana
    Assie, Guillaume
    Bancos, Irina
    Brue, Thierry
    Buchfelder, Michael
    Chabre, Olivier
    Ceccato, Filippo
    Daniele, Andrea
    Detomas, Mario
    Di Dalmazi, Guido
    Elenkova, Atanaska
    Findling, James
    Grossman, Ashley B.
    Gomez-Sanchez, Celso E.
    Heaney, Anthony P.
    Honegger, Juergen
    Karavitaki, Niki
    Lacroix, Andre
    Laws, Edward R.
    Losa, Marco
    Murakami, Masanori
    Newell-Price, John
    Giraldi, Francesca Pecori
    Perez-Rivas, Luis G.
    Pivonello, Rosario
    Rainey, William E.
    Sbiera, Silviu
    Schopohl, Jochen
    Stratakis, Constantine A.
    Theodoropoulou, Marily
    van Rossum, Elisabeth F. C.
    Valassi, Elena
    Zacharieva, Sabina
    Rubinstein, German
    Ritzel, Katrin
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (03) : P1 - P16
  • [4] Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations
    Reincke, Martin
    Albani, Adriana
    Assie, Guillaume
    Bancos, Irina
    Brue, Thierry
    Buchfelder, Michael
    Chabre, Olivier
    Ceccato, Filippo
    Daniele, Andrea
    Detomas, Mario
    Di Dalmazi, Guido
    Elenkova, Atanaska
    Findling, James
    Grossman, Ashley B.
    Gomez-Sanchez, Celso E.
    Heaney, Anthony P.
    Honegger, Juergen
    Karavitaki, Niki
    Lacroix, Andre
    Laws, Edward R.
    Losa, Marco
    Murakami, Masanori
    Newell-Price, John
    Giraldi, Francesca Pecori
    Perez-Rivas, Luis G.
    Pivonello, Rosario
    Rainey, William E.
    Sbiera, Silviu
    Schopohl, Jochen
    Stratakis, Constantine A.
    Theodoropoulou, Marily
    van Rossum, Elisabeth F. C.
    Valassi, Elena
    Zacharieva, Sabina
    Rubinstein, German
    Ritzel, Katrin
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 184 (03) : P1 - P16
  • [5] From Nelson's Syndrome to Corticotroph Tumor Progression Speed: An Update
    Bessiene, Laura
    Villa, Chiara
    Bertagna, Xavier
    Baussart, Bertrand
    Assie, Guillaume
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024,
  • [6] Pregnancy Does Not Accelerate Corticotroph Tumor Progression in Nelson's Syndrome
    Jornayvaz, Francois R.
    Assie, Guillaume
    Bienvenu-Perrard, Marie
    Coste, Joel
    Guignat, Laurence
    Bertherat, Jerome
    Silvera, Stephane
    Bertagna, Xavier
    Legmann, Paul
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : E658 - E662
  • [7] Progression Rate of Silent Corticotroph Adenomas After Stereotactic Radiosurgery
    Chen, Shao-Ching
    Chung, Wen-Yuh
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (05): : 1113 - 1114
  • [8] Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression
    Demarchi, Gianina
    Perrone, Sofia
    Esper Romero, Gaela
    De Bonis, Cristian
    Casasco, Juan Pablo
    Sevlever, Gustavo
    Berner, Silvia Ines
    Cristina, Carolina
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [9] Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor
    Perez-Rivas, Luis G.
    Theodoropoulou, Marily
    Puar, Troy H.
    Fazel, Julia
    Stieg, Mareike R.
    Ferrau, Francesco
    Assie, Guillaume
    Gadelha, Monica R.
    Deutschbein, Timo
    Fragoso, Maria C.
    Kusters, Benno
    Saeger, Wolfgang
    Honegger, Juergen
    Buchfelder, Michael
    Korbonits, Marta
    Bertherat, Jerome
    Stalla, Guenter K.
    Hermus, Ad R.
    Beuschlein, Felix
    Reincke, Martin
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 178 (01) : 57 - 63
  • [10] Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor
    Nakano-Tateno, Tae
    Satou, Motoyasu
    Inoshita, Naoko
    van Landeghem, Frank K. H.
    Easaw, Jay
    Mehta, Vivek
    Tateno, Toru
    Chik, Constance L.
    [J]. ENDOCRINE PATHOLOGY, 2021, 32 (03) : 418 - 426